Acute liver failure

R D Hughes, J Wendon, A E S Gimson

Institute of Liver Studies, King's College Hospital and School of Medicine and Dentistry, London
R D Hughes
J Wendon
A E S Gimson

Correspondence to:
Dr Robin Hughes,
Institute of Liver Studies,
King's College School of
Medicine and Dentistry,
Bessemer Road, London SE5.

Acute liver failure is a rare disorder with hepatic encephalopathy occurring within eight weeks of the onset of symptoms, without previous chronic liver disease, it has a high mortality of up to 80% in many series. In 1973 the Liver Failure Unit, the first of its kind, was built at King's as a specific intensive care facility to treat such critically ill patients. Since then over 1000 cases of fulminant hepatic failure have been referred and the Unit has acquired an international reputation as a centre for developing treatment strategies and research. This has been facilitated by two Medical Research Council Programme Grants and more recently by recognition for national funding as a specialised Supraregional Service.

In 1973 the survival from fulminant hepatic failure with grade 4 encephalopathy was about 20%, but as is shown in the Figure, since then a steady improvement has been observed with survival rates of over 50% in some aetiological groups. This chapter will highlight some of the major advances that have appeared from the more than 100 published papers that have been produced from the liver failure research group and that have led to the improved survival figures. It is, of course, not possible to acknowledge the efforts of all the research and clinical staff involved in this over the years in this short review. For a comprehensive account up to 1986 see ref 1.

A major milestone in liver failure research at King's was the International Symposium on Artificial Liver Support for Acute Liver Failure held in 1974, where many of the problems associated with this condition and its management were identified. Recently, in September 1990, the 11th BSG/SK & F International Workshop was held on Acute Liver Failure: Improved Understanding and Better Therapy. A small group of people all working in this field met to review the progress made to date, some of which is included in this chapter and also the chapter on liver transplantation in this volume. There was no doubt considerable progress has been made.

Aetiology and pathogenesis

Paracetamol hepatotoxicity was recognised early to be an important cause of fulminant hepatic failure[2] and remains the most common cause in the United Kingdom. Paracetamol is metabolised by the cytochrome P450 system with production of an unstable reactive metabolite N-acetyl-p-benzoquinoneimine which is rapidly inactivated by conjugation with glutathione. In overdosage, as glutathione stores are depleted accumulation of the active metabolite causes cell damage. This cell damage can be prevented by sulphydryl donors such as cysteamine, methionine, and N-acetylcysteine. The latter has usually been recommended only if it can be given within 16 hours of the overdose, but a retrospective survey showed significant benefit even if given at up to 48 hours. Fewer patients progressed to grade 4 encephalopathy and the mortality was lower in those cases receiving late N-acetylcysteine administration compared with other cases presenting at a similar time after the overdose and with similar prolongation of the prothrombin time.[3] More recently preliminary analysis of a randomised clinical trial of late N-acetylcysteine administration has also shown a lower mortality in the treated cases. Improvements in survival with the later use of N-acetylcysteine, when most of the paracetamol has been cleared, probably results from mechanisms unconnected with the direct binding of N-acetylcysteine to the reactive metabolite, as when given early.

Viral hepatitis is the most common cause of fulminant hepatic failure worldwide with fulminant hepatitis B virus the most prevalent variety in many areas. A fulminant course is more common in the presence of coinfection of hepatitis D with hepatitis B virus, but may also be related to an enhanced antibody response to the virus. Compared with cases of uncomplicated acute viral hepatitis, those with a fulminant course have a higher antiHBc titre and more rapid clearance of HBsAg from serum which may lead to antigen-antibody complex deposi-

Improvements in survival, according to aetiology, of patients with fulminant hepatic failure (grades III and IV encephalopathy) admitted to the Liver Failure Unit at King's College Hospital from 1973 to 1990. The figure includes patients who underwent liver transplantation.

tion in hepatic sinusoids and ischaemic necrosis of hepatocytes. Pathogenetic mechanisms of fulminant hepatitis A and non-A, non-B are unknown but significant differences occur in the clinical course and complication rates between the three types.[4] Thus fulminant viral hepatitis A has a shorter duration before the onset of encephalopathy, a lower peak prothrombin time and cerebral oedema is less common compared with presumed non-A, non-B where the patients tend to be older, with a slower onset of encephalopathy and a worse mortality.

Idiosyncratic drug reactions are an important cause of fulminant hepatic failure and have been recorded after a wide range of drugs including isoniazid, non-steroidal anti-inflammatory drugs, monoamine oxidase inhibitors, valproate and ketoconazole, but the most common occurring in up to 5% of all cases referred to the Liver Failure Unit follows halothane anaesthesia. Liver failure may develop up to 21 days after halothane exposure often in obese women with a history of atopy and previous minor pyrexial reactions to anaesthetics. Hepatotoxicity may be immunologically mediated as antibodies to halothane exposed rabbit hepatocytes are found in up to 80% of cases.[5]

Coagulation abnormalities

Studies on the severe abnormalities in coagulation in relation to bleeding stem from the often referred to seminal work of Rake *et al* on intravascular coagulation in liver failure.[6] Increased susceptibility to bleeding in acute liver failure results from both consumption and lack of synthesis of clotting factors and their inhibitors, as well as a low platelet count. Originally a number of trials to replace depleted clotting factors using fresh frozen plasma and factor IX concentrates to reduce bleeding and heparin to stop intravascular coagulation were carried out by Clark, Gazzard and others with little overall success. Further studies were stimulated as a result of the problems with biocompatibility of artificial liver support. In these Weston *et al* investigated platelet function and found that platelet aggregation to classical stimuli was impaired and platelet ultrastructure was abnormal. Platelet stickiness was found to be increased consistent with activated platelets remaining in the circulation because of lack of clearance by the damaged liver. Factor VIII is involved in platelet adhesion to foreign surfaces and is the only clotting factor found at increased concentrations in fulminant hepatic failure, probably as it originates from vascular endothelial cells. All three components of factor VIII were found by Langley *et al*[7] to be at concentrations over three times normal in liver failure, suggesting involvement of factor VIII in the platelet reactions. Difficulties of anticoagulation during extracorporeal circulation in these patients led Sette *et al* to study heparin clearance and response in liver failure and it was found that there was more rapid elimination of heparin and increased heparin sensitivity which helps explain the basis of this problem. Further confirmation of ongoing activation of the coagulation and platelet systems was obtained when highly sensitive assays became available; fibrinopeptide A for thrombin action, fibrinopeptide Bβ 1–42 for plasmin action, β-thromboglobulin and platelet factor 4 for platelet activation. Plasma levels of all these were higher than normal, but not to the degree seen in true disseminated intravascular coagulation.[8]

Recent studies by Langley *et al* have concentrated on the role of coagulation inhibitors in the consumptive coagulopathy of liver failure. Antithrombin III, is the major inhibitor of coagulation and was found to occur at very low levels in patients with acute liver failure. Two controlled clinical trials of replacement therapy have been carried out with a heat treated antithrombin III concentrate produced by Behring. As antithrombin III is a heparin cofactor, we evaluated supplementation during haemodialysis in liver failure. Antithrombin III levels were normalised, less heparin was administered and losses of platelets were significantly reduced. In the other trial, the effect of antithrombin III supplementation was assessed in patients with septic shock associated with liver failure. The rationale for this being that intravascular coagulation is most severe in this group of patients and could underlie multiple organ failure. Despite correction of antithrombin III levels the high mortality in this group was not improved and it was considered that earlier therapy might have been more successful. Protein C is a potent inhibitor of factor V and VIII and as with other clotting factors was found at low levels in fulminant hepatic failure, suggesting that supplementation might be worthy of study.

The relationship between infection and the coagulation derangement was investigated further from the plasma levels of leucocyte elastase measured by the presence of elastase α_1-antitrypsin complexes. Greater release of elastase was found in liver failure patients who had bacterial infection and this correlated with reduced plasma fibrinogen and increased thrombin-antithrombin complexes another sensitive marker of thrombin formation. Thus it is likely that infection with the associated cytokine release is interrelated with activation of the coagulation system.

Artificial liver support

Early attempts at liver support at King's included exchange transfusion and pig liver perfusion, which were impractical to perform on a regular basis. The concept of artificial liver support based on haemoperfusion through adsorbents to remove the wide range of toxins accumulating in the circulation is still attractive. Experimental work by Wilson, Dunlop and others led to the clinical use of charcoal haemoperfusion, as pioneered by TMS Chang in Canada. A column of polymer-coated activated charcoal to remove water soluble toxins was developed in association with Smith and Nephew Research. The exciting results in the first patients were reported in the *Lancet* by Gazzard *et al*,[9] with 10 of the 22 patients in grade IV encephalopathy treated surviving. Further patients had severe hypotensive episodes, however, which were shown by Weston *et al* to be

related to the formation of platelet aggregates in the extracorporeal circuit. Alternative means of patient treatment were needed and hence the use of polyacrylonitrile dialysis with a high permeability membrane. After laboratory studies on agents to inhibit the platelet reactions; charcoal haemoperfusion with prostacyclin (PGI_2) was started in 1980. Subsequently Gimson *et al*[10] reported results in 76 patients, with a survival rate of up to 65% in patients treated early, when still in grade III coma. There had been considerable debate about the question of performing a clinical trial of charcoal haemoperfusion over the years, original plans were shelved due to the problems of blood compatibility. This was finally resolved when two clinical trials were performed, five hours *versus* 10 hours haemoperfusion in patients with grade III and 10 hours haemoperfusion *versus* intensive care alone in patients with grade IV encephalopathy. No significant differences were found in these two groups in 137 patients entered. Overall survival was good and was related to aetiology, being best in paracetamol overdose and viral hepatitis A and B and worst in non-A, non-B hepatitis and adverse reactions to drugs.[11] It was considered that these results were the result of the improving background of intensive care management which masked any earlier benefits of charcoal haemoperfusion.

Together with the original work on charcoal there was interest in an adsorbent to remove lipid soluble toxins. A resin column was developed in the Unit based on Amberlite XAD-7 coated with human serum albumin to confer good blood compatibility, which was confirmed in *in vitro* experiments. A successful pilot study was carried out in patients and larger scale production of the columns by Immuno AG in Vienna allowed evaluation of serial resin haemoperfusion in 19 patients with fulminant hepatic failure.[12] Blood compatibility was confirmed and removal of bilirubin, bile acids and substances in the middle molecular weight range (1000–5000) demonstrated. A larger column was produced to increase removal, but with some loss of biocompatibility. Unfortunately, at this point commercial development had to be stopped. We are still interested in artificial liver support for removal of specific substances using plasma rather than whole blood perfusion to try and avoid blood cell activation.

A number of laboratory studies on the toxins accumulating in liver failure were carried out at the same time as the haemoperfusion work. Fulminant hepatic failure serum was shown to contain substances inhibitory to membrane sodium transport both in leucocytes by Alam and Poston[13] and in brain by Seda *et al*.[14] Membrane ultrafiltration (<10 kD) followed by column chromatography on Sephadex G–25 produced four fractions which contained the inhibitory activity. Resin and charcoal haemoperfusion were shown to be complementary in removing these Na^+,K^+–ATPase inhibitors. Subsequently some of the peaks were shown to crossreact with antibodies to digoxin, an inhibitor of Na^+,K^+–ATPase, making this radioimmunoassay useful for monitoring toxin removal in artificial liver support.[15]

Cerebral oedema

The mechanisms involved in the development of hepatic encephalopathy and the associated cerebral oedema in acute liver failure remain ill defined. Cerebral oedema remains the most common cause of death in fulminant hepatic failure as originally reported from the Unit,[16] although there has been considerable progress in its management. The importance of this complication was first shown in post mortem studies and in an animal model of liver failure, but in 1980 Hanid *et al* reported the first use of an intracranial pressure monitor in patients with fulminant hepatic failure. Dramatic rises in intracranial pressure were observed, often spontaneous but occasionally precipitated by external events, which importantly preceeded clinical evidence of cerebral oedema (opisthotonus, pupillary abnormalities, respiratory arrest).

Rises in intracranial pressure occur in up to 80% of cases of fulminant hepatic failure and management rests on maximising cerebral perfusion pressure and cerebral blood flow, both of which tend to fall as intracranial pressure rises. The patient is nursed flat with minimal stimulation, pCO_2 maintained at 3·5–4 kPa and core temperature normalised. Attempts to prevent the development of cerebral oedema with dexamethasone as used in head injury were unsuccessful. In a large controlled clinical trial Canalese *et al*[17] showed that cases that did not develop cerebral oedema had a 60% survival whereas in those in whom it did develop and who did not receive mannitol survival was 10%. Mannitol therapy was highly effective in reducing a raised intracranial pressure and significantly improved survival. This was the first randomised trial in fulminant hepatic failure to show an improved survival with a defined treatment modality and represented an important advance.

Current studies are attempting to investigate the relationship between intracranial pressure, mean arterial pressure, cerebral perfusion pressure and cerebral blood flow as well as less invasive methods to monitor cerebral blood flow. Jugular bulb cannulation with continuous measurement of venous oxygen saturation shows encouraging results as a continuous index of cerebral blood flow.

Parallel laboratory studies were performed to investigate the possible mechanisms involved in the development of cerebral oedema. Changes in blood-brain barrier permeability could allow solutes into brain which would give rise to an increased water content. Zaki *et al*[18] showed an increase in blood-brain barrier transport of inulin in a rat model of liver failure. Later, ultrastructural studies showed that the tight junctions in the cerebral capillaries were intact indicating that the breakdown of the blood-brain barrier was functional rather than structural suggesting vasogenic mechanisms of oedema formation are less important. Inhibition of membrane transport would be consistent with a cytotoxic mechanism of cerebral oedema. Inhibition of Na^+,K^+–ATPase activity, a key enzyme of sodium transport, and increased brain water content were found in experiments using the galactosamine rat model of liver failure,[19]

although dehydration of the animals limited the degree of oedema.

Host defences and sepsis

It has long been recognised that a significant proportion of the mortality from fulminant hepatic failure can be attributed to the high incidence of sepsis that is so frequently seen. Investigation and documentation of this increased susceptibility to infection has been a topic of much research at the Liver Unit over the years. Studies by Wyke *et al* showed defective opsonisation of *E coli* and yeasts by serum of patients with fulminant hepatic failure, the aetiology for this defect was ascribed to complement deficiency with components of both the classical and alternative pathways being reduced to below 40% of that found in control serum. Neutrophil adherence was also noted to be significantly impaired by Altin *et al*, and this impaired adherence along with complement deficiency and depressed opsonisation result in an overall significant impairment in host defences against infection. Both the plasma level of fibronectin, an important component of the reticuloendothelial system and *in vitro* plasma opsonisation activity were found by Imawari *et al* to be significantly depressed in patients with fulminant hepatic failure and the level of fibronectin correlated with the degree of impairment of opsonisation activity. Significant impairment of Kupffer cell function was elegantly demonstrated by Canalese *et al* in patients with fulminant hepatic failure using clearance of microaggregated albumin.[20] Impaired Kupffer cell function was associated with encephalopathy and a significant improvement in function at 48 hours was seen in those patients who survived. By contrast hepatocyte dysfunction was equally impaired in patients with acute hepatic necrosis with and without encephalopathy, highlighting the possible importance of the relationship between Kupffer cells and hepatocytes in the aetiology of encephalopathy. Fibronectin replacement in patients with fulminant hepatic failure was studied by Hughes *et al*, this resulted in an increase in *in vitro* plasma opsonisation activity, however, clearance of microaggregated albumin remained unchanged as did oxygen consumption, suggesting that other factors are responsible. The incidence of infection in patients with fulminant hepatic failure has recently been reported by Rolando *et al*,[21] showing a 80% infection rate in patients with fulminant hepatic failure, of great interest was the finding that infecting organisms were gram positive in 50% of cases and were nosocomial in nature. Further work by Rolando *et al* has also indicated a surprisingly high incidence of fungal infection in fulminant hepatic failure, occurring in 30% of patients.

Haemodynamics

The haemodynamic and cardiovascular disturbances of fulminant hepatic failure have long been an interest of the Liver Unit. In 1977 Weston *et al* described a frequent incidence of cardiac dysrhythmias and electrocardiographic abnorm-

alities in patients with fulminant hepatic failure, malignant arrythmias being more frequent in patients with hypoxia, acidosis and hyperkalaemia. Macroscopic cardiac abnormalities were found in 64% of patients at necropsy, these comprising scattered peticheal haemorrhages, pericardial effusions and fatty pale ventricles. The pathophysiology of the hypotension seen in fulminant hepatic failure was first investigated by Trewby *et al*. In this paper it was shown that the hypotension of fulminant hepatic failure was related to peripheral vasodilation rather than primary myocardial failure, and that volume loading frequently resulted in an increase in cardiac output and a resultant increase in mean arterial pressure. Trewby *et al* also noted the presence of low pressure pulmonary oedema in fulminant hepatic failure, this finding being frequently associated with the presence of severe cerebral oedema raising the possibility of neurogenic pulmonary oedema in patients with fulminant hepatic failure. Work by Bihari and Gimson resulted in detailed study and further investigation of the haemodynamic pathophysiology of fulminant hepatic failure, with the identification of pathological supply dependency for oxygen in such patients. Significant differences between survivors and non-survivors was noted, with lower systemic vascular resistance indices, oxygen extraction ratio and higher blood lactates in non-surviving patients.[22] Only in survivors was the *in vivo* P_{50} related to the oxygen extraction ratio. In addition it was noted that mixed venous lactate correlated with systemic vascular resistance index, mean arterial pressure and oxygen extraction ratio.[23] These data suggest that in patients with fulminant hepatic failure there is a disturbance of the microcirculation resulting in a tissue oxygen debt that is greater in patients that fail to survive. The use of prostacyclin, a microcirculatory vasodilator in such patients results in an increase in oxygen uptake, with the possibility of lessening or reversing the covert tissue oxygen debt. More recently the effects of vasopressor agents have been studied. Although these agents improve mean arterial pressure they have a detrimental effect on peripheral oxygen extraction ratio and oxygen consumption resulting in tissue hypoxia and this effect on peripheral oxygen uptake can be reversed by the use of prostacyclin in addition to vasopressor agents. The aetiological events that result in a tissue oxygen debt in patients with fulminant hepatic failure are poorly understood but relate to the development of interstitial oedema, white cell and platelet plugs and functional arteriovenous shunts. Cytokines are almost certainly important mediators resulting in these microcirculatory changes. Recent work by Sheron *et al* has shown raised levels of cytokines in fulminant hepatic failure with interleukin–6 (a marker of endothelial activation) correlating with hypotension, cerebral oedema, systemic vascular resistance index, oxygen extraction ratio, oxygen consumption and pH.

Hepatic regeneration

Liver regeneration is ultimately responsible for survival in liver failure, but the processes in-

volved are only recently beginning to become elucidated at the molecular level. Serum from patients with fulminant hepatic failure was shown by Hughes *et al* to be cytotoxic to rabbit hepatocytes and subsequently in 1985 Gove *et al*[24] showed that fulminant hepatic failure serum was inhibitory to DNA synthesis in isolated regenerating rat hepatocytes. This was confirmed in *in vivo* experiments in partially hepatectomised rats by Yamada *et al*.[25] Injection of fulminant hepatic failure serum at the time of maximal DNA synthesis inhibited the incorporation of ^{3}H-thymidine into hepatic DNA. These effects were greater with sera from patients with fulminant hepatic failure because of non-A, non-B hepatitis and adverse reactions to drugs compared with patients with fulminant hepatic failure caused by paracetamol overdose and hepatitis A and B. The inhibitory activity was associated with a less than 10 kD fraction of serum and this could be further resolved into two fractions by gel chromatography corresponding to approximate molecular weights of 2 kD and 5 kD.

The isolation and purification of a highly potent human hepatocyte growth factor (hHGF) was recently reported by workers from Japan.[26] High concentrations of this factor were found in sera of patients with fulminant hepatic failure, particularly in those who died. This suggests that the poor liver regeneration in certain groups of patients is not caused by lack of this stimulatory factor. In which case identification of the inhibitory factors found at King's is of even greater importance.

Recommendations for treatment

The previous sections of this chapter have given a selected overview of the main areas of therapeutic study and have led to certain generalisations about overall treatment strategies for fulminant hepatic failure. All patients with grade 3 or 4 hepatic encephalopathy should receive dextrose infusion and H_2-receptor blockers as originally described by the late Brian Macdougall. Intermittant positive pressure ventilation to maintain $PaCO_2$ at 4–4·5 kPa should be started and the patient nursed with 10° head up position. Mannitol, 20% solution, should be given for episodes of cerebral oedema detected either by clinical criteria or intracranial pressure monitoring and supplemented by haemofiltration if renal failure is present. Machine driven dialysis should be avoided and continuous arteriovenous haemofiltration is the preferred renal replacement therapy. Close microbiological surveillance will reveal septic episodes and dictate the appropriate antibiotic policy. Finally, in those cases in whom the prognostic criteria indicate a survival of less than 10%, orthotopic liver transplantation remains the best chance of prolonged survival.

The future

Numerous avenues of new treatment and research are opening up in fulminant hepatic failure. Not all can be mentioned in this review but studies into the mechanisms of hepatocellular necrosis and attempts to prevent this

process will be of prime importance. Preliminary studies from Toronto on the use of PGE_1 infusion as a hepatoprotective agent have been encouraging start to this approach, but await formal trials. When events at the sinusoidal level and cellular level which lead to cell death are better understood, more rational treatment strategies could then be developed.

The concept of circulating toxins that are not cleared by the failing liver and are responsible for the end organ damage of fulminant hepatic failure has a long history. Nevertheless, recent anecdotal reports of significant improvements in intracranial pressure and haemodynamics in patients with fulminant hepatic failure in whom the liver is removed some hours before orthotopic liver transplantation have raised the possibility that the necrotic liver itself is releasing toxic substances with systemic effects on organ function and microcirculatory blood flow. Identification of these substances and attempts to remove them by extracorporeal devices or by neutralisation with monoclonal antibodies will be of key importance, as well as earlier removal of the necrotic liver in patients selected for liver transplantation.

Because of the high frequency of clinically significant bacterial and fungal sepsis during fulminant hepatic failure the possibility of prophylactic treatment has been raised. Systemic parenteral and enteral decontamination regimes have been shown to be of use in critically ill patients in intensive care units. A trial is currently in progress to assess the benefit and side effects of prophylactic parenteral and enteral decontamination.

The future investigation of the haemodynamics of fulminant hepatic failure requires elucidation and investigation of agents involved in the control of the microcirculation, such as the endothelins, endothelium-derived relaxant factor, thromboxanes and prostacyclin. Improved understanding of the role of these agents and their interaction with tumour necrosis factor and the interleukins will allow greater manipulation of the microcirculation. Compounds to promote nutritive microcirculatory flow could be administered and detrimental agents removed with appropriate monoclonal antibodies. Such a strategy would limit tissue hypoxia and hence the multiple organ damage that is so frequently seen in fulminant hepatic failure and results in such an increase in mortality.

In recent years there has been much study of the mechanisms of control and initiation of liver cell regeneration. Identification of hepatic stimulatory substances and inhibitors of regeneration and investigation of the ability of the surviving hepatocytes to respond to these stimuli will all yield important results.

Hepatocyte transplantation and heterotopic liver transplantation to tide the patient over a period of severe hepatocellular dysfunction, with the patient retaining their own liver, is also another promising area for future investigation.

1 Williams R, ed. Fulminant hepatic failure. *Semin Liver Dis* 1986; 6: No. 2.
2 Toghill PJ, Williams R, Stephens JD, Carroll JD. Acute hepatic necrosis following an overdose of paracetamol. *Gastroenterology* 1969; 56: 773–6.

3 Harrison PM, Keays R, Bray GP, Alexander GJM, Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. *Lancet* 1990; 335: 1572–3.

4 Gimson AES, White YS, Eddleston ALWF, Williams R. Clinical and prognostic differences in fulminant hepatitis type A, B and non-A, non-B. *Gut* 1983; 24: 1194–8.

5 Vergani D, Mieli-Vergani G, Alberti A, *et al.* Demonstration of a circulating antibody reacting with the surface membrane of halothane-altered hepatocytes in patients with fulminant hepatitis following halothane anaesthesia. *N Engl J Med* 1980; 303: 66–71.

6 Rake MO, Flute PT, Pannell G, Williams R. Intravascular coagulation in acute hepatic necrosis. *Lancet* 1970; i: 533–7.

7 Langley PG, Hughes RD, Williams R. Increased factor VIII complex in fulminant hepatic failure. *Thrombosis Haemostasis* 1985; 54: 693–6.

8 Hughes RD, Lane DA, Ireland H, Langley PG, Gimson AES, Williams R. Fibrinogen derivatives and platelet activation products in acute and chronic liver disease. *Clin Sci* 1985; 68: 701–7.

9 Gazzard BG, Weston MJ, Murray-Lyon IM, *et al.* Charcoal haemoperfusion in the treatment of fulminant hepatic failure. *Lancet* 1974; i: 1301–7.

10 Gimson AES, Braude S, Mellon PJ, Canalese J, Williams R. Earlier charcoal haemoperfusion in fulminant hepatic failure. *Lancet* 1982; ii: 681–3.

11 O'Grady JG, Gimson AES, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal haemoperfusion and prognostic factors in fulminant hepatic failure. *Gastroenterology* 1988; 94: 1186–92.

12 Bihari D, Hughes RD, Gimson AES, *et al.* Effects of serial resin haemoperfusion in fulminant hepatic failure. *Int J Artif Organs* 1983; 6: 299–302.

13 Alam AN, Poston L, Wilkinson SP, Golindano CG, Williams R. A study *in vitro* of the sodium pump in fulminant hepatic failure. *Clin Sci Mol Med* 1978; 55: 355–63.

14 Seda HWM, Hughes RD, Gove CD, Williams R. Inhibition of rat brain Na^+, K^+-ATPase activity by serum from patients with fulminant hepatic failure. *Hepatology* 1984; 4: 74–9.

15 Yang S-S, Hughes RD, Williams R. Digoxin-like immunoreactive substances in severe acute liver disease due to viral hepatitis and paracetamol overdose. *Hepatology* 1988; 8: 93–7.

16 Gazzard BG, Portmann B, Murray-Lyon IM, Williams R. Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. *Q J Med* 1975; 44: 615–26.

17 Canalese J, Gimson AES, Davis C, Mellon PJ, Davis M, Williams R. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. *Gut* 1982; 23: 625–9.

18 Zaki AEO, Ede RJ, Davis M, Williams R. Experimental studies of the blood brain barrier in acute hepatic failure. *Hepatology* 1984; 4: 359–64.

19 Ede RJ, Gove CD, Hughes RD, Marshall W, Williams R. Reduced brain Na^+, K^+-ATPase activity in rats with galactosamine-induced hepatic failure: relationship to encephalopathy and cerebral oedema. *Clin Sci* 1987; 72: 365–71.

20 Canalese J, Gove CD, Gimson AES, Wilkinson SP, Wardle EN, Williams R. Reticuloendothelial system and hepatocyte function in fulminant hepatic failure. *Gut* 1982; 23: 265–9.

21 Rolando N, Harvey F, Brahm J, *et al.* Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. *Hepatology* 1990; 11: 49–53.

22 Bihari D, Gimson AES, Waterson M, Williams R. Tissue hypoxia during fulminant hepatic failure. *Crit Care Med* 1985; 13: 1034–9.

23 Bihari D, Gimson AES, Lindridge J, Williams R. Lactic acidosis in fulminant hepatic failure. Some aspects of pathogenesis and prognosis. *J Hepatol* 1985; 1: 405–16.

24 Gove CD, Hughes RD, Williams R. Rapid inhibition of DNA synthesis in hepatocytes from regenerating rat livers by serum from patients with fulminant hepatic failure. *Br J Exp Pathol* 1982; 63: 547–53.

25 Yamada H, Hughes RD, Gove CD, Williams R. Effects of fulminant hepatic failure serum on hepatic DNA synthesis in normal and partially hepatectomised rats. *Eur J Gastroenterol Hepatol* 1990; 2: 483–8.

26 Gohda H, Tsubouchi H, Nakayama H, *et al.* Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. *J Clin Invest* 1988; 81: 414–9.